EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate

Romain Aubry iD, Julien M Buyck iD, Alexia Chauzy iD, Laure Prouvensier, Jean-Winoc Decousser iD, Patrice Nordmann iD, Sebastian G Wicha, Sandrine Marchand iD, Nicolas Grégoire iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01797-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Romain Aubry und 8 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1070 PHAR2, Université de Poitiers, Poitiers, Nouvelle-Aquitaine, France. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, Azabicyclo Compounds, Colistin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inoculum effect (IE) characterizes a decrease in the antimicrobial effect of antibiotics with increasing inoculum. To face antimicrobial resistance, antibiotic combinations are progressively used. In this context, the effect of combination may be affected by IE, especially drugs for which an IE has been described. The objective was to characterize the IE of a carbapenemase (KPC-3) Klebsiella pneumoniae isolate on the combination of ceftazidime/avibactam (CZA) and colistin (CST). In vitro time-kill curves with single and combined drugs were performed at four different inocula. The IE of each drug was described using pharmacokinetic/pharmacodynamic modeling, and interactions on IE were investigated with the general pharmacodynamic interaction model when drugs were combined. The IE was assessed by evaluating the significance of the parameters associated with the IE model compared to the no IE model and by comparing the CFU counts over time predicted with the IE model vs the no IE model. Rapid bacterial killing was observed at 10 4 CFU/mL. For both 5·10 5 and 10 7 CFU/mL inocula, initial decays followed by re-growth were observed with drugs alone, while the combination prevented the emergence of resistance. Eradication was never achieved at 10 8 CFU/mL. The IE was best modeled as a reduction of CZA maximum bactericidal effect and as an increase in CST EC 50 with increasing inoculum. However, no interaction between IEs was significant, meaning that CST did not modify the IE of CZA and inversely. IE may be important at least as demonstrated by in vitro antibiotic combination studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeKlebsiella pneumoniaeAzabicyclo CompoundsColistinAnti-Bacterial Agentsbeta-LactamasesMicrobial Sensitivity TestsDrug CombinationsBacterial ProteinsKlebsiella Infections

Stichwörter der Autor:innen

PKPD modelingantimicrobial combinationceftazidime/avibactamcolistininoculum effect

Substanzen

CeftazidimeAzabicyclo CompoundsColistinAnti-Bacterial Agentsavibactam, ceftazidime drug combinationDrug Combinationsbeta-LactamasesBacterial Proteinsbeta-lactamase KPC-3, Klebsiella pneumoniaecarbapenemase

Autor:innen und Institutionen

  • INSERM U1070 PHAR2, Université de Poitiers, Poitiers, Nouvelle-Aquitaine, France.
  • Laboratoire de Toxicologie et de Pharmacocinétique, CHU de Poitiers, Poitiers, Nouvelle-Aquitaine, France.
  • Department of Bacteriology and Infection Control, University Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France.
  • EA 7380 Dynamyc Université Paris-Est Créteil (UPEC), Ecole nationale vétérinaire d'Alfort (EnvA), Faculté de Médecine de Créteil, Créteil, France.
  • Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.

ORCID-Profile: Romain Aubry, Julien M Buyck, Alexia Chauzy, Jean-Winoc Decousser, Patrice Nordmann, Sandrine Marchand, Nicolas Grégoire

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Aubry, R., Buyck, J. M., Chauzy, A., Prouvensier, L., Decousser, J. W., Nordmann, P., Wicha, S. G., Marchand, S., & Grégoire, N. (2025). PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01797-24

Vancouver

Aubry R, Buyck JM, Chauzy A, Prouvensier L, Decousser JW, Nordmann P, et al. PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01797-24

BibTeX
@article{Aubry2025,
  author = {Aubry, Romain and Buyck, Julien M and Chauzy, Alexia and Prouvensier, Laure and Decousser, Jean-Winoc and Nordmann, Patrice and Wicha, Sebastian G and Marchand, Sandrine and Grégoire, Nicolas},
  title = {PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01797-24}
}
Kostenlos starten →